<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82924">
  <stage>Registered</stage>
  <submitdate>23/06/2008</submitdate>
  <approvaldate>18/07/2008</approvaldate>
  <actrnumber>ACTRN12608000341325</actrnumber>
  <trial_identification>
    <studytitle>Effects of dietary administration of n-3 polyunsaturated fatty acids on cardiac electrophysiology in humans</studytitle>
    <scientifictitle>Effects of dietary administration of n-3 polyunsaturated fatty acids on cardiac electrophysiology in humans undergoing cardiac electrophysiology testing and/or ablation for supraventricular tachycardia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>supraventricular tachycardia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>liquid fish oil containing 18% eicosapentaenoic acid (EPA) + 12% docosahexaenoic acid (DHA). 15 ml/day for 21 days days prior to electrophysiology study/ablation</interventions>
    <comparator>liquid sunola oil (high oleic acid sunflower oil). 15 ml/day for 21 days immediately prior to electrophysiology study/ablation</comparator>
    <control>Placebo</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Atrial refractory periods at a) high lateral right atrium b) low lateral right atrium c) proximal coronary sinus d) distal coronary sinus e) High atrial septum</outcome>
      <timepoint>at time of electrophysiology study/ablation ie at day 21</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Conduction velocity: a) Total conduction time (lateral right atrium to distal coronary sinus), b) Coronary sinus, c) Lateral right atrium</outcome>
      <timepoint>at time of electrophysiology study/ablation ie at day 21</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>corrected sinus node recovery time</outcome>
      <timepoint>at time of electrophysiology study/ablation ie at day 21</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Wenckebach cycle length of the atrio-ventricular node</outcome>
      <timepoint>at time of electrophysiology study/ablation ie at day 21</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>undergoing an elective cardiac electrophysiology procedure (electrophysiology study +/- ablation for supraventricular tachycardia</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a) Cardiac rhythm other than sinus rhythm at the time of the procedure
b) Current use of fish oil supplements
c) Known impaired lipid metabolism
d) Uncontrolled diabetes mellitus
e) Known allergy to fish 
f) Current use of anti-arrhythmics other than ÃŸ-blockers, or use of amiodarone within the past 3 months 
g) New York Heart Association Grade II-IV heart failure
h) Known bleeding disorder</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subject enrolled during consultation with physician, who will telephone trial manager for next subject number and group allocation</concealment>
    <sequence>computer generated
http://www.random.org/integers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Tce
Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation of Australia</fundingname>
      <fundingaddress>Level 12, 500 Collins Street
Melbourne VIC 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In this study, we will examine the effects of n-3 fatty acids on the electrophysiology of the heart in a bid to determine possible mechanisms for anti-arrhythmic effects of n-3 fatty acids</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>North Tce
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert Metcalf</name>
      <address>level4 Eleanor Harrald Bldg
Royal Adelaide Hospital
North Tce
Adelaide SA 5000</address>
      <phone>61 8 82225581</phone>
      <fax>61 8 82225895</fax>
      <email>robert.metcalf@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Robert Metcalf</name>
      <address>Level4 Eleanor Harrald Bldg
Royal Adelaide Hospital
North Tce
Adelaide SA 5000</address>
      <phone>08 82225581</phone>
      <fax>08 82225895</fax>
      <email>robert.metcalf@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Robert Metcalf</name>
      <address>level4 Eleanor Harrald Bldg
Royal Adelaide Hospital
North Tce
Adelaide SA 5000</address>
      <phone>08 82225581</phone>
      <fax>08 82225895</fax>
      <email>robert.metcalf@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>